9.20
price up icon1.32%   0.12
after-market アフターアワーズ: 9.24 0.04 +0.43%
loading
前日終値:
$9.08
開ける:
$9.12
24時間の取引高:
3.01M
Relative Volume:
2.12
時価総額:
$437.72M
収益:
$91.06M
当期純損益:
$-503.14M
株価収益率:
-1.0965
EPS:
-8.39
ネットキャッシュフロー:
$-424.74M
1週間 パフォーマンス:
-0.86%
1か月 パフォーマンス:
+40.89%
6か月 パフォーマンス:
+49.84%
1年 パフォーマンス:
-13.37%
1日の値動き範囲:
Value
$9.105
$9.22
1週間の範囲:
Value
$9.04
$9.28
52週間の値動き範囲:
Value
$4.62
$13.47

Sage Therapeutics Inc Stock (SAGE) Company Profile

Name
名前
Sage Therapeutics Inc
Name
セクター
Healthcare (1160)
Name
電話
617-299-8380
Name
住所
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
職員
487
Name
Twitter
@SageBiotech
Name
次回の収益日
2025-02-11
Name
最新のSEC提出書
Name
SAGE's Discussions on Twitter

SAGE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SAGE
Sage Therapeutics Inc
9.20 437.72M 91.06M -503.14M -424.74M -8.39
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
459.62 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.36 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.91 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
543.48 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.49 28.51B 3.81B -644.79M -669.77M -6.24

Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-03-11 再開されました BofA Securities Underperform
2024-11-21 アップグレード RBC Capital Mkts Underperform → Sector Perform
2024-10-10 再開されました Raymond James Mkt Perform
2024-10-04 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2024-07-30 ダウングレード TD Cowen Buy → Hold
2024-07-25 ダウングレード JP Morgan Overweight → Neutral
2024-05-29 開始されました Citigroup Sell
2024-05-29 開始されました Robert W. Baird Neutral
2024-04-17 ダウングレード BofA Securities Neutral → Underperform
2023-12-12 開始されました Deutsche Bank Hold
2023-08-08 ダウングレード Canaccord Genuity Buy → Hold
2023-08-08 ダウングレード Goldman Buy → Neutral
2023-08-08 ダウングレード Needham Buy → Hold
2023-08-07 ダウングレード BofA Securities Buy → Neutral
2023-08-07 ダウングレード Oppenheimer Outperform → Perform
2023-08-07 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-08-07 ダウングレード Stifel Buy → Hold
2023-08-07 ダウングレード Wedbush Outperform → Neutral
2023-07-27 開始されました Scotiabank Sector Outperform
2023-03-13 アップグレード RBC Capital Mkts Sector Perform → Outperform
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-11-01 開始されました Loop Capital Hold
2022-03-31 開始されました Berenberg Hold
2021-11-02 アップグレード Guggenheim Neutral → Buy
2021-10-19 再開されました Morgan Stanley Equal-Weight
2021-10-07 ダウングレード Jefferies Buy → Hold
2021-09-23 開始されました Needham Buy
2021-06-16 ダウングレード Citigroup Buy → Neutral
2021-04-07 開始されました Piper Sandler Overweight
2021-02-26 ダウングレード Mizuho Buy → Neutral
2021-02-25 繰り返されました H.C. Wainwright Neutral
2021-02-02 再開されました Raymond James Mkt Perform
2021-01-22 ダウングレード BMO Capital Markets Outperform → Market Perform
2021-01-04 アップグレード Guggenheim Neutral → Buy
2021-01-04 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-12-04 アップグレード Mizuho Neutral → Buy
2020-12-01 ダウングレード Raymond James Outperform → Mkt Perform
2020-11-16 ダウングレード Morgan Stanley Overweight → Equal-Weight
2020-11-06 繰り返されました H.C. Wainwright Neutral
2020-09-11 アップグレード Wedbush Neutral → Outperform
2020-08-10 アップグレード Raymond James Mkt Perform → Outperform
2020-05-08 ダウングレード Wedbush Outperform → Neutral
2020-04-08 ダウングレード Guggenheim Buy → Neutral
2020-03-18 アップグレード RBC Capital Mkts Sector Perform → Outperform
2020-03-06 開始されました Citigroup Buy
2020-02-28 繰り返されました H.C. Wainwright Neutral
2020-02-06 開始されました Mizuho Neutral
2019-12-06 繰り返されました RBC Capital Mkts Outperform
2019-12-05 繰り返されました Guggenheim Buy
2019-12-05 ダウングレード SunTrust Buy → Hold
2019-10-30 開始されました H.C. Wainwright Neutral
2019-05-23 開始されました Wedbush Outperform
2019-04-25 開始されました Jefferies Buy
2018-12-14 開始されました Wolfe Research Outperform
2018-10-11 開始されました Oppenheimer Outperform
すべてを表示

Sage Therapeutics Inc (SAGE) 最新ニュース

pulisher
Jun 18, 2025

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc.SAGE - Business Wire

Jun 18, 2025
pulisher
Jun 18, 2025

H.C. Wainwright sees potential competition for Sage from Biogen - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire Sage Therapeutics stock for $8.50 per share - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Supernus to acquire depression drugmaker Sage - MSN

Jun 18, 2025
pulisher
Jun 17, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Update: Truist Securities Raises Price Target | SAGE - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (NasdaqVERV), Sage Therapeutics, Inc. (NasdaqSAGE), Cantaloupe, Inc. (NasdaqCTLP), Volato Group, Inc. (NYSE American - Morningstar

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Downgraded by Piper Sandler: Price Target Reduced | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - ACCESS Newswire

Jun 17, 2025
pulisher
Jun 17, 2025

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock? - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE: HC Wainwright Maintains Neutral Rating and $12 Price Target | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Considers Bid Amid Sage Therapeutics Merger Developments | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Biogen (BIIB) Involved in Sage Pharmaceuticals Acquisition Deal | BIIB Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Stock Rating Maintained as Price Target is Raised by Canacc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE Price Target Raised Amid Acquisition News | SAGE Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance

Jun 17, 2025
pulisher
Jun 17, 2025

Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone - Benzinga

Jun 17, 2025
pulisher
Jun 16, 2025

Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com

Jun 16, 2025
pulisher
Jun 16, 2025

Piper Sandler Downgrades Sage Therapeutics (SAGE) Following Acqu - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald

Jun 16, 2025
pulisher
Jun 16, 2025

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus’ $795 million bid sufficient for Sage - The Pharma Letter

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's

Jun 16, 2025
pulisher
Jun 16, 2025

Sage, following Setbacks, to sell to Supernus for $561M - BioPharma Dive

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics By Stocktwits - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus enters depression drug market with up to $795 million Sage deal - Reuters

Jun 16, 2025
pulisher
Jun 16, 2025

Truist Securities Adjusts SAGE Therapeutics Price Target to $9 From $8, Maintains Hold Rating - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR - TipRanks

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus to buy Sage for up to $795 million - Axios

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics Stock Explodes Over 35% in Massive Rally on Nasdaq - Daily Chhattisgarh News

Jun 16, 2025
pulisher
Jun 16, 2025

Transcript : Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc.M&A Call - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus strikes deal to buy Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

After rebuffing Biogen, Sage pairs off with Supernus - pharmaphorum

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Rating Reiterated as Hold by Needham | SAGE Stock New - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus - BioSpace

Jun 16, 2025
pulisher
Jun 16, 2025

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million - inkl

Jun 16, 2025
pulisher
Jun 16, 2025

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Jun 16, 2025
pulisher
Jun 16, 2025

Sage Therapeutics shares soar after supernus acquisition deal By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Wedbush Adjusts PT on SAGE Therapeutics to $8.50 From $6 on Heels of Announced Sale to Supernus; Maintains Neutral - marketscreener.com

Jun 16, 2025
pulisher
Jun 16, 2025

After brushing off Biogen, Mass. biotech firm finds buyer for $795M - NBC Boston

Jun 16, 2025
pulisher
Jun 16, 2025

Maryland firm outbids Biogen for Sage Therapeutics - The Business Journals

Jun 16, 2025
pulisher
Jun 16, 2025

Supernus Pharmaceuticals (SUPN) to Acquire Sage Therapeutics in $795M Deal - GuruFocus

Jun 16, 2025

Sage Therapeutics Inc (SAGE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.30
price down icon 0.68%
$36.37
price up icon 0.50%
$24.55
price up icon 8.53%
$97.80
price down icon 0.45%
$110.00
price up icon 1.61%
biotechnology ONC
$245.49
price up icon 0.48%
大文字化:     |  ボリューム (24 時間):